Unió Europea - búlgar - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - астма - Лекарства за обструктивна заболявания на дихателните пътища, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Unió Europea - búlgar - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - астма - Лекарства за обструктивна заболявания на дихателните пътища, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Unió Europea - búlgar - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - Анемия, сърповидна клетка - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Unió Europea - búlgar - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - Липидни модифициращи агенти - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Unió Europea - búlgar - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - Множествена Склероза, Рецидивно-Ремиттирующее - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

Unió Europea - búlgar - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - Карцином, недребноклетъчен белодроб - Антинеопластични средства - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Unió Europea - búlgar - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - Радиоюклидно изображение - Диагностични радиофармацевтици - Този лекарствен продукт е само за диагностична употреба. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Unió Europea - búlgar - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - Новообразувания На Простатата, Кастраци-Упорит - Терапевтични радиофармацевтици - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Unió Europea - búlgar - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - Антинеопластични средства - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Unió Europea - búlgar - EMA (European Medicines Agency)

novartis europharm limited - еверолимус - carcinoma, renal cell; breast neoplasms; pancreatic neoplasms - Антинеопластични средства - Хормон-рецептор-положителен-често на гърдата cancerafinitor е показан за лечение на хормон-рецептор-позитивен her2/neu-отрицателен предварителни рак на гърдата, в комбинация с exemestane, в стълб-menopausal жени без симптоматично висцералната патология, след рецидив или прогресия на заболяването след non-steroidal и abs битор. Нейроэндокринные тумори на панкреаса originafinitor е показан за лечение на неоперабельной или метастатичен, добре или умерено диференцирани нейроэндокринные тумори на панкреаса произход при възрастни с белег заболяване. Нейроэндокринные тумори на стомашно-чревния тракт или на белите дробове originafinitor е показан за лечение на неоперабельной или метастатичен добре диференцирани (от клас 1 или от клас 2) излизане от строй нейроэндокринные тумори на стомашно-чревния или белодробен произход при възрастни с белег заболяване. Почечно-клетъчен carcinomaafinitor е показан за лечение на пациенти с честата почечно-клетъчен карцином, болест на които развивало след обработка на vegf-таргетной терапия.